| Nov 1 |
Evolus to Participate in Stifel 2024 Healthcare Conference
|
| Oct 31 |
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
|
| Oct 31 |
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
|
| Oct 30 |
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
|
| Oct 29 |
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
|
| Oct 23 |
Evolus to Report Third Quarter Financial Results on November 6, 2024
|
| Oct 12 |
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 10 |
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
|
| Oct 9 |
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
|
| Oct 3 |
A Closer Look at 5 Analyst Recommendations For Evolus
|
